Antimutagenic and Antiapoptotic Effects of Aqueous Root Extract of Inula racemosa Hook. f. on 4-NQO-Induced Genetic Damage in Mice

Phytochemical Diversity in Relation to Cytogenetic Variability in Inula racemosa Hook.f., an Endangered Medicinal Plant of Himalayas

Inula racemosa, a resourceful critically endangered medicinal herb in the Himalayas is traditionally utilized to cure various human disorders. The species is a wealthy source of sesquiterpene lactones has many pharmacological properties. To quantify and identify the best genetic stocks for a maximum build-up of desired metabolites (isoalantolactone and alantolactone) among existent cytotypes in the species, LC-MS/MS analysis was made. The other comprehensive experiments carried out at present included detailed meiotic examinations of different populations collected from different areas of Kashmir Himalayas. The results presented the occurrence of variable chromosome numbers as n=10 and n=20 in different populations, but the tetraploid cytotype (n=20) is new for the species. The LC-MS/MS investigation revealed significant variability in the content of sesquiterpene lactones in different plant tissues (stem, leaf, and root). An upsurge in the quantity of isoalantolactone and alantolactone was noticed with increasing ploidy levels along the increasing altitudes. Therefore, a habit to accumulate abundant quantities of secondary metabolites and increased adaptability by species/cytotypes thriving at higher altitudes is seen among tetraploid cytotypes during the present investigation. Also, the chromosomal variations seem to enhance the flexibility of polyploid species primarily at upper elevations. Thus, the present study strongly provides quantification of elite cytotypes/chemotypes with optimum concentration of secondary metabolites.

Ethnopharmacology, phytochemistry, agrotechnology, and conservation of Inula racemosa Hook f. - A critically endangered medicinal plant of the western Himalaya

ETHNOPHARMACOLOGICAL RELEVANCE

Inula racemosa Hook. f., is a critically endangered perennial herb distributed throughout the Himalaya; commercially useful in pharmaceutical products mainly because of its expectorant, antispasmodic, hypotensive, anti-inflammatory, carminative, thermogenic, digestive, cardiotonic, acrid, alexipharmic, anodyne, aphrodisiac, febrifuge, and antiseptic properties. The roots including rhizomes of the plant were used in the treatment of various ailments like chest pain, liver dysfunction, dyspnoea, and cardiovascular diseases by the ethenic Himalayan residents.

AIM OF THE REVIEW

Even though there are plentiful studies involving I. racemosa for pharmacological properties, but there is gap or few records available on production technologies and patents. The purpose of review is to provide large unmanageable information in systematic form for researchers, health care contributors, and policy makers so that they efficiently integrate the existing information and provide balanced decision making.

MATERIALS AND METHODS

Relevant data search was completed through systematic searches using various scientific databases including e-resources viz., Scopus, Google Scholar, Science Direct, ACS, Springer Link, Taylor and Francis, Scifinder, PubMed, PubChem, Web of Science, LibGen, Wiley, and China National Knowledge Infrastructure (CNKI). The list of literature cited in this review are dated from 1959 to 2021.

RESULTS

Till date variety of ethnobotanical and pharmacological properties of essential oil including crude extract of I. racemosa have been documented. The shortlisted records revealed that the herb has a potential to treat stomach ulcer, respiratory tract infections including chronic obstructive pulmonary disease (COPD). Alantolactone and isoalloalantolactone were reported as the major bioactive constituents along with few fatty acids, phytosterols, and glycosides characterized by GC, GC/MS, HPLC, HPTLC and qNMR techniques.

CONCLUSIONS

Based on a detailed literature survey on the plant, evidences were found fascinating for biological, traditional, and pharmacological effects, whilst there are no genomic resources available for this medicinal herb. Thus, molecular studies are critical for unravelling the production process of bioactive metabolites inside herb, which will underlay a path for improving these metabolites at commercial scale. Moreover, the association and role of particular phytoconstituent in its biological properties still needs to be validated. In addition, there are no reports on measures on its conservation and mechanism of toxicity research, which also needs more attention. We hope this review can provide a basis for further studies concerning the protected and efficient utilization of I. racemosa.

Cytotoxicity and molecular docking analysis of racemolactone I, a new sesquiterpene lactone isolated from Inula racemosa

CONTEXT

Traditionally, Inula racemosa Hook. f. (Asteraceae) has been reported to be effective in cancer treatment which motivated the authors to explore the plant for novel anticancer compounds.

OBJECTIVE

To isolate and characterize new cytotoxic phytoconstituents from I. racemosa roots.

MATERIALS AND METHODS

The column chromatography of I. racemosa ethyl acetate extract furnished a novel sesquiterpene lactone whose structure was established by NMR (1D/2D), ES-MS and its cytotoxic properties were assessed on HeLa, MDAMB-231, and A549 cell lines using MTT and LDH (lactate dehydrogenase) assays. Further, morphological changes were analyzed by flow cytometry, mitochondrial membrane potential, AO-EtBr dual staining, and comet assay. Molecular docking and simulation were performed using Glide and Desmond softwares, respectively, to validate the mechanism of action.

RESULTS

The isolated compound was identified as racemolactone I (compound 1). Amongst the cell lines tested, considerable changes were observed in HeLa cells. Compound 1 (IC50 = 0.9 µg/mL) significantly decreased cell viability (82%) concomitantly with high LDH release (76%) at 15 µg/mL. Diverse morphological alterations along with significant increase (9.23%) in apoptotic cells and decrease in viable cells were observed. AO-EtBr dual staining also confirmed the presence of 20% apoptotic cells. A gradual decrease in mitochondrial membrane potential was observed. HeLa cells showed significantly increased comet tail length (48.4 µm), indicating broken DNA strands. In silico studies exhibited that compound 1 binds to the active site of Polo-like kinase-1 and forms a stable complex.

CONCLUSIONS

Racemolactone I was identified as potential anticancer agent, which can further be confirmed by in vivo investigations.

A New Cytotoxic Dimeric Sesquiterpene Isolated from Inula racemosa Hook. f. (Root): In Vitro and In Silico Analyses

A new dimeric sesquiterpene named disesquicin (compound 1) was isolated from Inula racemosa roots by normal-phase MPLC (Medium Pressure Liquid Chromatography), and its structure was established by using extensive spectral analysis. Compound 1, when tested on different human cancer cell lines, showed marked cytotoxic activity (IC50 (µg/mL): 5.99 (MDA-MB), 9.10 (HeLa), and 12.47 (A549)). Docking study revealed that it binds at the catalytic domain of PLK-1 and interacts with catalytic site residues Leu59, Gly60, Lys61, Gly62, Cys67, Ala80, Lys82, Leu130, Arg136, Ser137, Leu139, Glu140, Lys178, Gly180, Asn181, Phe183, and Asp194. The binding of compound 1 to PLK-1 is spontaneous in nature as evident by a free energy of—8.930 kcal mol−1, corresponding to a binding affinity of 3.54 × 106 M−1. Results showed that compound 1 exhibited cytotoxic potential that was further confirmed by in vivo investigations.

Phytochemical analysis and differential in vitro cytotoxicity assessment of root extracts of Inula racemosa

The root of Inula racemosa is known for its antifungal, hypolipdemic and antimicrobial properties in traditional Indian Ayurvedic and Chinese system of medicine. The biological efficacy of Inula species is mainly due to the presence sesquiterpene lactone (Isoalantolactone and Alantolactone), which are reported to be inducers of Nrf2 antioxidant pathway. The investigation of properties and efficacy of root extracts of I. racemosa and their comparison was done with a view to find most efficacious extract for use at cellular level (both normal and transformed). In the present study different extracts of root of I. racemosa (aqueous, ethanolic, and 50% aqueous-ethanolic) were prepared and compared for their antioxidant potential, reducing capacity, polyphenol content and flavonoid content. Our investigations suggested that the aqueous extract possess highest antioxidant capacity and reducing potential. The polyphenol content was found to be highest in aqueous extract in comparison with other two extracts. However, all the three extracts showed less flavonoid content. Further, the preliminary phytochemical screening of all the extracts revealed the presence of terpenoids, phytosterols and glycosides. The TLC profile of ethanolic and 50% aqueous-ethanolic extracts showed the presence of alantolactone while aqueous extracts did not exhibit its strong presence. This warrants the need of more stringent techniques for characterization of aqueous extract in future. The in vitro cell based toxicity assays revealed that the aqueous extract was less toxic to kidneys cells while ethanolic extract was toxic to cells even at low concentrations. Hence, the current investigations showed better efficacy of the aqueous extract with respect to other extracts and found to be promising for its future application at in vitro levels.